Belbuca is an opioid film patch and aims to treat patients with chronic pain who need round-the-clock treatment and for whom current alternatives do not suffice.
The patch is expected to be commercially available in the United States by the 1st quarter ending March in 7 dosages, BioDelivery said.
Belbuca is placed on the inner lining of the cheek, leading to faster delivery of analgesic drug buprenorphine directly into the bloodstream.
Buprenorphine has a lower abuse potential than most opioid medications. The Belbuca treatment can also prevent misuse through snorting or injecting as the film patch is difficult to crush or liquefy.
Given the lower possibilities of misuse as seen with buprenorphine, physicians can write a six-month prescription as opposed to writing one on a strict monthly basis.
“It (buprenorphine) is an easier drug to write,” Laidlaw analyst Jim Molloy said.
Since most of the drug is absorbed through the cheek and with little going through the digestive tract, Belbuca could potentially lead to lower constipation, a common side effect that most oral drugs are known to cause, Molloy said.
Molloy expects the treatment to rake in peak U.S. sales of about $450 million by 2018 for Endo, and about $80 million for BioDelivery. He said Belbuca accounts for $12 of his $17 price target on BioDelivery’s shares.
The abuse of opioids, a class of drugs that include heroin and prescription painkillers, has long been a concern in the U.S. An overdose of prescription painkillers can produce euphoric highs and even disrupt parts of the brain that control breathing.
The approval comes a little more than a month after the FDA staff flagged dosage concerns over Collegium Pharmaceutical’s opioid drug, Xtampza, and Purdue Pharma’s fast-acting oxycodone painkiller.
The approval also triggers a $50 million milestone payment by Endo to BioDelivery as part of a licensing agreement signed in 2012. The company will also receive royalties on U.S. net sales of the drug.
BioDelivery’s shares, which closed at $5.28 Oct. 23, were at $6.50 before the bell.
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.